Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | GLA | P06280 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA9 | Q16790 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31078533 | 1.00 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL2552940 | 0.85 | KDM4E (0.61) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL29416299 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL68952 | 0.84 | KDM4E (0.70) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL9107394 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL21104992 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL31291300 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL11932172 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL1025153 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL2568123 | 0.80 | CA12 (0.56) | KDM4EALDH1A1GAAGLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104424-A1 | SARM1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| EP-4741397-A1 | FUSED TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Zhongge Biological Technology Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| CN-119528923-A | Tri-fused ring compound and preparation method and application thereof | 韦恩生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-119060053-A | Nuclear receptor binding SET structural domain protein 2/3 inhibitor, and pharmaceutical composition and application thereof | 深圳众格生物科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118724916-A | Polyaryl-containing macrocyclic compounds and uses thereof | 浙江养生堂天然药物研究所有限公司 | 2024-10-01 | — | — | CN | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118146212-A | PARP7 inhibitor and preparation method and application thereof | 成都先导药物开发股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117580831-A | GRK2 inhibitors and uses thereof | 索纳塔治疗公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20070112198-A1 | Method for manufacture of thip | H.LUNDBECK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070112198-A1 | Method for manufacture of thip | H.LUNDBECK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| WO-2007027855-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1664060-A1 | METHOD FOR THE MANUFACTURE OF THIP | H. Lundbeck A/S (DK) | 2006-06-07 | — | — | EP | disclosed |
| EP-1534679-A2 | INHIBITORS OF POST-AMADORI ADVANCED GLYCATION END PRODUCTS | Biostratum, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005023820-A1 | METHOD FOR THE MANUFACTURE OF THIP | H. LUNDBECK A/S (DK) | 2005-03-17 | — | — | WO | disclosed |
| US-20040122061-A1 | Inhibitors of post-amadori advanced glycation end products | BIOSTRATUM, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004019889-A2 | INHIBITORS OF POST-AMADORI ADVANCED GLYCATION END PRODUCTS | BIOSTRATUM, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112198-A1 | Method for manufacture of thip | GABBR1, GABBR2, GABRQ | KDM4E 1365/4885ALDH1A1 843/4885GAA 2004/4885 |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | KDM4E 3956/4885ALDH1A1 1842/4885GAA 2019/4885 |
| US-20040122061-A1 | Inhibitors of post-amadori advanced glycation end products | AGER, GLA, OGA | KDM4E 2055/4885ALDH1A1 175/4885GAA 4/4885 |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | KDM4E 680/4885ALDH1A1 373/4885GAA 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.